Shreya Mukhopadhyay1, Kelly Fellows1, Richard W Browne2, Prachi Khare2, Sandhya Krishnan Radhakrishnan2, Jesper Hagemeier3, Bianca Weinstock-Guttman4, Robert Zivadinov5, Murali Ramanathan6. 1. Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, USA. 2. Department of Biotechnical and Clinical Laboratory Sciences, The State University of New York at Buffalo, Buffalo, NY, USA. 3. Buffalo Neuroimaging Analysis Center, Department of Neurology, The State University of New York at Buffalo, Buffalo, NY, USA. 4. Department of Neurology, The State University of New York at Buffalo, Buffalo, NY, USA. 5. Buffalo Neuroimaging Analysis Center, Department of Neurology, The State University of New York at Buffalo, Buffalo, NY, USA/Department of Neurology, The State University of New York at Buffalo, Buffalo, NY, USA. 6. Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, USA/Buffalo Neuroimaging Analysis Center, Department of Neurology, The State University of New York at Buffalo, Buffalo, NY, USA.
Abstract
PURPOSE: To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers. METHODS: This study included 550 subjects (203 HC, 221 relapsing-remitting MS (RR-MS), 126 progressive MS (P-MS)). A complete lipid profile including total cholesterol (TC); high-density lipoprotein-cholesterol (HDL-C); low-density lipoprotein-cholesterol (LDL-C); apolipoproteins (Apo) A1, A2, B, and E; C-reactive protein (CRP); 24-hydroxycholesterol (HC); 25-HC; 27-HC; 7α-HC; and 7-ketocholesterol (KC) was obtained. Lipoprotein particle sizing by proton nuclear magnetic resonance (H1 NMR) was available for 432 subjects. RESULTS: The levels of 24-HC, 27-HC, and 7α-HC (all p < 0.015) were lower in MS compared to HC, and 7-KC was higher in P-MS compared to RR-MS ( p < 0.001). TC, LDL-C, and ApoB were associated with higher levels of all oxysterols (all p < 0.05) in HC. In MS, LDL-C was associated with higher levels of 24-HC, 25-HC, 7-KC, and 7α-HC (all p < 0.05), while TC and ApoB were associated with increased levels of all oxysterols (all p < 0.005). CONCLUSION: The findings of lower 24-HC, 27-HC, and 7α-HC in MS compared to HC and higher 7-KC in P-MS compared to RR-MS indicate that the oxysterol network is disrupted in MS.
PURPOSE: To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers. METHODS: This study included 550 subjects (203 HC, 221 relapsing-remitting MS (RR-MS), 126 progressive MS (P-MS)). A complete lipid profile including total cholesterol (TC); high-density lipoprotein-cholesterol (HDL-C); low-density lipoprotein-cholesterol (LDL-C); apolipoproteins (Apo) A1, A2, B, and E; C-reactive protein (CRP); 24-hydroxycholesterol (HC); 25-HC; 27-HC; 7α-HC; and 7-ketocholesterol (KC) was obtained. Lipoprotein particle sizing by proton nuclear magnetic resonance (H1 NMR) was available for 432 subjects. RESULTS: The levels of 24-HC, 27-HC, and 7α-HC (all p < 0.015) were lower in MS compared to HC, and 7-KC was higher in P-MS compared to RR-MS ( p < 0.001). TC, LDL-C, and ApoB were associated with higher levels of all oxysterols (all p < 0.05) in HC. In MS, LDL-C was associated with higher levels of 24-HC, 25-HC, 7-KC, and 7α-HC (all p < 0.05), while TC and ApoB were associated with increased levels of all oxysterols (all p < 0.005). CONCLUSION: The findings of lower 24-HC, 27-HC, and 7α-HC in MS compared to HC and higher 7-KC in P-MS compared to RR-MS indicate that the oxysterol network is disrupted in MS.
Authors: Leonie A Boven; Marjan Van Meurs; Marloes Van Zwam; Annet Wierenga-Wolf; Rogier Q Hintzen; Rolf G Boot; Johannes M Aerts; Sandra Amor; Edward E Nieuwenhuis; Jon D Laman Journal: Brain Date: 2005-12-19 Impact factor: 13.501
Authors: F Chalmin; V Rochemont; C Lippens; A Clottu; A W Sailer; D Merkler; S Hugues; C Pot Journal: J Autoimmun Date: 2014-11-10 Impact factor: 7.094
Authors: Simon Zhornitsky; Kyla A McKay; Luanne M Metz; Charlotte E Teunissen; Manu Rangachari Journal: Mult Scler Relat Disord Date: 2015-10-19 Impact factor: 4.339
Authors: Elizabeth S Gold; Alan H Diercks; Irina Podolsky; Rebecca L Podyminogin; Peter S Askovich; Piper M Treuting; Alan Aderem Journal: Proc Natl Acad Sci U S A Date: 2014-07-03 Impact factor: 11.205
Authors: Kawita M S Kanhai; Sebastiaan C Goulooze; Jeroen van der Grond; Amy C Harms; Thomas Hankemeier; Ajay Verma; Gersham Dent; Juan Chavez; Henri Meijering; Geert Jan Groeneveld Journal: Clin Transl Sci Date: 2021-11-19 Impact factor: 4.689